MedTrace Logo

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

NCT01499953 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2023-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).

Conditions

  • Superficial Vein Thrombosis

Interventions

DRUG

Rivaroxaban

Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral

DRUG

Fondaparinux

Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • Jan Beyer-Westendorf, MD · on behalf of GWT-TUD GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499953 on ClinicalTrials.gov